FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Para fines de investigación únicamente. Aviso completo →

Investigación/Highlight the current state of knowledge on mitochondrial-derived peptides (MDPs) and their potential as therapeutic agents in diabetes management, emphasizing evolutionary perspectives.
Volver a Biblioteca de Investigación
HumaninMOTS-cSHLP1-6

Highlight the current state of knowledge on mitochondrial-derived peptides (MDPs) and their potential as therapeutic agents in diabetes management, emphasizing evolutionary perspectives.

May 16, 2026
Share

Fuente del Paper

Mitochondrial-derived peptides: Antidiabetic functions and evolutionary perspectives.

Kal Satadeepa et al.Peptides2024
Investigación Emergente

Basado en investigación emergente. Estos hallazgos son prometedores pero requieren validación adicional.

Sobre este análisis

Este artículo descompone los hallazgos del paper fuente anterior en lenguaje accesible para la comunidad de investigación de péptidos. Nuestro objetivo es destacar lo más importante — las implicaciones prácticas, la fuerza de la evidencia y lo que significa para la investigación en curso.

Mitochondrial-Derived Peptides: A New Frontier in Diabetes Treatment?

Published: May 16, 2026 | Source: Peptides (2024) | Category: Humanin, MOTS-c, SHLP1-6

Overview

Recent research has shed light on a novel class of peptides called mitochondrial-derived peptides (MDPs), which are encoded by short open-reading frames in the mitochondria's DNA. These MDPs—Humanin (HN), MOTS-c, and small Humanin-like peptides (SHLP1-6)—show promise as potential therapeutic agents for managing diabetes, particularly Type 1, Type 2, and gestational diabetes. Understanding their evolutionary conservation provides insights into their biological significance.

Study Background

Before this study, MDPs were known to play roles in various cellular processes but their specific functions in diabetes management remained unclear. Researchers sought to explore the antidiabetic properties of these peptides and understand why they have been conserved throughout evolution despite being encoded by a small portion of mitochondrial DNA.

What the Research Found

The review highlights that MDPs, such as Humanin (HN), MOTS-c, and SHLP1-6, play crucial roles in regulating glucose metabolism and insulin sensitivity. For instance, HN has been shown to protect pancreatic beta cells from oxidative stress-induced apoptosis, which is a significant factor in the progression of Type 1 diabetes. Similarly, MOTS-c enhances insulin secretion and improves glucose tolerance in animal models of Type 2 diabetes.

SHLP peptides also exhibit antidiabetic properties but their mechanisms are less understood compared to HN and MOTS-c. The review emphasizes that these peptides use unique genetic codes different from those used by nuclear DNA, which underscores the complexity and specificity of mitochondrial gene expression.

What This Means for Peptide Users

While this research provides a strong theoretical framework for the potential therapeutic benefits of MDPs in diabetes management, it does not yet translate into clinical applications. Further studies are needed to validate these findings through clinical trials and to determine safe dosages and delivery methods for human use.

Limitations and Caveats

As a review paper, this study relies heavily on existing literature rather than presenting new experimental data or clinical trial results. Consequently, the claims about MDP functions in diabetes management need further validation through rigorous scientific investigation. Additionally, the evolutionary conservation of these peptides does not necessarily imply their therapeutic efficacy; more research is required to confirm this.

How This Compares to Previous Research

Previous studies have also highlighted the potential roles of MDPs in various diseases, including neurodegenerative disorders and cancer. However, this review specifically focuses on diabetes management and evolutionary perspectives, providing a unique angle that complements existing knowledge.

Our Analysis

PeptideVault views this research as an important step towards understanding the multifaceted roles of mitochondrial-derived peptides. The paper effectively synthesizes current literature to highlight potential therapeutic avenues but acknowledges the need for further experimental validation. Its emphasis on evolutionary conservation adds depth to our understanding of these peptides' biological significance, though it does not directly translate into immediate clinical applications.

Key Takeaways

  • Evolutionary Conservation: MDPs have been conserved across species due to their critical roles in cellular processes.
  • Antidiabetic Potential: Humanin (HN), MOTS-c, and SHLP1-6 show promise in managing Type 1, Type 2, and gestational diabetes but require further clinical validation.
  • Unique Genetic Codes: MDPs use distinct genetic codes compared to nuclear DNA, highlighting the complexity of mitochondrial gene expression.

Original Source

Citation: Kal Satadeepa, Mahata Sumana, Jati Suborno et al. (2024). Mitochondrial-derived peptides: Antidiabetic functions and evolutionary perspectives.. Peptides. DOI: 10.1016/j.peptides.2023.171147

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Nota del Editor

Este análisis fue preparado por el equipo de investigación de Peptide Contacts. Se anima a los lectores a revisar la fuente completa del paper para metodología y datos completos. La publicación original está disponible en PubMed.

Investigación Relacionada

Comments

Sign in to join the discussion

Este análisis se genera a partir de investigación revisada por pares para fines educativos solo. No constituye consejo médico. Consulte siempre a un proveedor de atención médica calificado antes de usar cualquier terapia basada en péptidos.